Oppenheimer raised the firm’s price target on Tarsus Pharmaceuticals (TARS) to $65 from $63 and keeps an Outperform rating on the shares.

The Company's full financial statements and related MD&A for the first quarter ended September 30, 2024, are available at www.inmedpharma.com, www.sedar.com and at www.sec.gov.

For years, Nigeria has faced significant challenges in procuring affordable, high-quality medicines due to the high cost of ...

After reaching a $6.01 billion deal with 3M to settle the largest mass tort litigation in U.S. history, lawyers for the ...

Mondi, a sustainable packaging and paper company, has completed a €90m ($95.3m) upgrade at its Mszczonów corrugated packaging ...

Stantec, alongside Hensel Phelps and Jones Studio, has secured a $274.7m contract from the US General Services Administration ...

In this week’s “Rising High,” The Fly’s recurring series focused on cannabis and psychedelic stock news, The Fly looks ...

InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary ...

Microsoft Gaming CEO Phil Spencer talked about the controversal price of Sony's new PS5 Pro, says 'we're not going to grow ...

The projected global photoacoustic microscopy market opportunity is likely to hit the USD 120 billion valuation mark by 2024.